NASDAQ · QNCX
Healthcare · Biotechnology
$33.93
Up+$1.82 (+5.67%)
Updated Aug 23, 2026, 10:18 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
QNCX closed at $33.93 after 20 trading sessions, up 90.08% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $32.77 | $34.085 | $32.57 | $33.93 | 9.54K |
| Aug 20, 2026 | $34.57 | $35.15 | $31.62 | $32.11 | 23.33K |
| Aug 19, 2026 | $32.89 | $35.23 | $31.25 | $34.57 | 23.4K |
| Aug 18, 2026 | $33.00 | $34.86 | $32.27 | $32.91 | 28.62K |
| Aug 17, 2026 | $34.95 | $35.41 | $33.08 | $34.12 | 38.99K |
| Aug 14, 2026 | $31.78 | $35.20 | $31.78 | $34.04 | 26.18K |
| Aug 13, 2026 | $30.89 | $33.7371 | $30.89 | $32.41 | 34.48K |
| Aug 12, 2026 | $32.92 | $33.26 | $30.0397 | $31.26 | 44.13K |
| Aug 11, 2026 | $31.50 | $33.11 | $30.5001 | $32.73 | 35.22K |
| Aug 10, 2026 | $30.00 | $31.47 | $29.68 | $30.65 | 33.7K |
| Aug 7, 2026 | $29.92 | $30.77 | $29.25 | $30.20 | 30.36K |
| Aug 6, 2026 | $29.17 | $30.32 | $28.5517 | $29.54 | 26.12K |
| Aug 5, 2026 | $27.16 | $29.99 | $27.16 | $28.88 | 42.79K |
| Aug 4, 2026 | $25.36 | $27.48 | $24.8097 | $27.41 | 26.38K |
| Aug 3, 2026 | $23.505 | $26.615 | $23.50 | $24.965 | 54.41K |
| Jul 31, 2026 | $23.47 | $24.59 | $21.55 | $23.39 | 35.3K |
| Jul 30, 2026 | $21.81 | $23.66 | $21.7647 | $23.03 | 58.79K |
| Jul 29, 2026 | $19.51 | $22.4099 | $18.4269 | $22.00 | 80.5K |
| Jul 28, 2026 | $17.47 | $19.37 | $17.36 | $19.37 | 37.63K |
| Jul 27, 2026 | $17.72 | $18.49 | $17.60 | $17.85 | 18.09K |
The latest Smart Investors Daily articles mentioning QNCX.
QNCX research
Company profile and research snapshot.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 29, 2026 | Oppenheimer | Outperform | — |
| Jun 24, 2026 | Leerink Partners | Outperform | — |
| Jun 23, 2026 | Cantor Fitzgerald | Overweight | — |
| Jan 30, 2026 | D. Boral Capital | Hold | — |
No generated briefing is available yet.
Benzinga · Aug 18, 2026
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Quince Therapeutics (NASDAQ:QNCX) with a Overweight and maintains $70 price target.
Benzinga · Aug 14, 2026
Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the analyst consensus estimate of $(26.32) by 53.21 percent. This is a 81.9 percent increase over losses of $(68.00) per share
Benzinga · Jul 31, 2026
-SEC Filing
Yahoo · Jul 29, 2026
Apple upgraded, Qualcomm downgraded: Wall Street's top analyst calls
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QNCX.
